¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20
±³À°ÀÏÀÚ : 2020-11-20
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2020 KALC International Conference      
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ½ÉÇöÁ¤ 
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í       
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:00~08:40 Tumor Infiltrating Lymphocytes and the Microenvironment as Biomarkers for Lung Cancer  David Rimm(Yale University School of Medicine) 
È޽Ġ11¿ù 20ÀÏ  08:40~08:50 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:50~09:30 Present and Future Perspectives of First-Line Checkpoint Inhibitor for Stage IV Nonsmall Cell Lung Cancer  David Carbone(The Ohio State University) 
È޽Ġ11¿ù 20ÀÏ  09:30~09:40 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 09:40~10:05 Harms, benefits and cost effectiveness of lc screening  Harry J. de Koning(Erasmus University Medical Center) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:05~10:30 LDCT Screening in Non-Smokers in Taiwan  Pan-Chyr Yang(National Taiwan University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:30~10:55 Imaging Biomarkers in Lung Cancer Screening  ±¸Áø¸ð(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:55~11:20 Liquid Biomarkers in Lung Cancer Screening  À̰迵(°Ç±¹ÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  11:20~11:30 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 11:30~12:20 Is it time for a paradigm shift in first line treatment of advanced NSCLC?  ±èÇý·Ã(¿¬¼¼ÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  12:20~12:40 Break&ÃÑȸ  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 12:40~13:05 Predictive Biomarkers for Efficacy of Immune Checkpoint Blockades in Lung Cancer  David Carbone(The Ohio State University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:05~13:30 Translation Research in Immunotherapy for Lung Cancer  Hidetoshi Hayashi(Kindai University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:30~13:55 Is HyperProgression Real, or How Do We Prepare for It?  ¼±Á¾¹«(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:55~14:20 If Less Is Good, More Is Better_Combination of ImmunoTx  ÀÌ´ëÈ£(¿ï»êÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  14:20~14:30 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 14:30~14:55 Evolution of Acquired Resistance to Targeted Therapies for Lung Cancer  Aaron Hata(Massachusetts General HospitalHarvard Medical School) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 14:55~15:20 Treatment for Advanced ALK, ROS1-Rearranged Lung Cancer  ±èµ¿¿Ï(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 15:20~15:45 Treatment for Advanced MET, RET-Altered Lung Cancer  Yasushi Goto(National Hospital Organization Kyushu Cancer Center) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 15:45~16:10 Treatment for Other Minor Mutations-Positive Advanced Lung Cancer  °­ÀºÁÖ(°í·ÁÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  16:10~16:20 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 16:20~16:45 E-Cigarettes and Vaping-Related Lung Injury  Jay H. Ryu(Mayo Clinic College of Medicine and Science) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 16:45~17:10 Current Status of Smoking Cessation with Heated Tobacco Products use in Japan  Takahiro Tabuchi(Osaka international Cancer institute) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 17:10~17:35 Current status of smoking cessation program in Korea and COVID-19 risk in smokers  ÃµÀº¹Ì(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 17:35~18:00 Pharmacotherapy for Smoking Cessation and Nicotine Dependence  ÃÖÇý¼÷(°æÈñÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÇǺΰúÀÇ»çȸ Á¦2ȸ ´ëÀü/¼¼Á¾/Ãæû Çмú ½ÉÆ÷Áö¿ò : 2020-11-21
´ÙÀ½±Û ´ëÇÑÆó¾ÏÇÐȸ (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20655 ¼­¿ï Á¦ 66ȸ Çѱ¹Ç×°ø¿ìÁÖÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-24 0 24 2024-05-10
20654 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-05-24 0 25 2024-05-10
20653 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24 0 22 2024-05-10
20652 ¼­¿ï Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 44 Â÷ KSTH Ãá°èÇмú´ëȸ : 2024-05-24 0 32 2024-05-10
20651 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚµÈ ÀÌ°ú Áúȯ : 2024-05-23 0 25 2024-05-10
20650 °æ±â Çϳ²½ÃÀÇ»çȸ¿¬¼ö°­ÁÂ(¸¸¼º±âħ, ºÒ¸éÁõ) : 2024-05-23 0 13 2024-05-10
20649 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-05-23 0 15 2024-05-10
20648 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦1Â÷¿¬¼ö±³À°(ºóÇ÷ ¹× ÃâÇ÷ Áúȯ, ÀÏÂ÷ ÀÇ·á±â°ü¿¡¼­ÀÇ °ü¸®) : 2024-05-23 0 24 2024-05-10
20647 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀüÃæûÁöȸ - Á¦2Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-23 0 33 2024-05-10
20646 Á¦ÁÖ ´ëÇÑÇǺΰúÇÐȸ Á¦ÁÖÁöºÎȸ 2024³â Á¦1Â÷ Áý´ãȸ : 2024-05-22 0 13 2024-05-10
20645 ´ë±¸ ´ëÇѾȰúÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö±³À°-¹é³»Àå ¹× Àü¾ÈºÎ ÃֽŠÁö°ß : 2024-05-21 0 12 2024-05-10
20644 ¼­¿ï ¾çõ±¸ÀÇ»çȸ Ãá°è¿¬¼ö±³À°(Á¦2Çü ´ç´¢º´°ú ¸¸¼º ½ÅÀ庴, ÀÎÁöÀå¾Ö, ¸ÞŸ¹ö½º¿Í ÀÇ·á Çõ¸í) : 2024-05-21 0 32 2024-05-10
20643 ÃæºÏ 2024 Á¦Ãµ½ÃÀÇ»çȸ Ãá°è ¿¬¼ö°­Á : 2024-05-21 0 8 2024-05-10
20642 ºÎ»ê Á¦28Â÷ ¾Æ½Ã¾Æ-¿À¼¼¾Æ´Ï¾Æ »êºÎÀΰú¿¬¸Í Çмú´ëȸ (AOFOG 2024) (4ÀÏÂ÷) : 2024-05-20 0 26 2024-05-10
20641 ¼­¿ï ´ëÇÑÀÓ»ó³ëÀÎÀÇÇÐȸ 2024 Ãá°è ³ëÀÎÀÇÇÐ ¿¬¼ö°­Á : 2024-05-19 0 67 2024-05-10
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷